Sonnet BioTherapeutics Announces Publication Demonstrating Suitability of SON-1210, the First Albumin-binding Bifunctional IL-12/IL-15 Fusion Protein, for Solid Tumor Immunotherapy
Stock Information for Sonnet BioTherapeutics Holdings Inc.
Loading
Please wait while we load your information from QuoteMedia.